



Comparative Transcriptional Profiling of Motor Neuron Disorder-Associated Genes in Various Human Cell Culture Models

Stefan Hauser^{1,2*}, Stefanie Schuster^{1,2,3}, Elena Heuten¹, Philip Höflinger^{1,2,3}, Jakob Admard⁴, Yvonne Schelling^{1,2}, Ana Velic⁵, Boris Macek⁵, Stephan Ossowski^{4,6} and Ludger Schöls^{1,2,6}

¹ German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany, ² Department of Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany, ³ Graduate School of Cellular and Molecular Neuroscience, University of Tübingen, Tübingen, Germany, ⁴ Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany, ⁶ Proteome Center Tübingen, University of Tübingen, Tübingen, Germany, ⁶ Center of Rare Diseases, University of Tübingen, Tübingen, Germany

OPEN ACCESS

Edited by:

Daniele Bottai, University of Milan, Italy

Reviewed by:

Xuejun Li, University of Illinois at Chicago, United States Allison Denise Ebert, Medical College of Wisconsin, United States

> *Correspondence: Stefan Hauser stefan.hauser@dzne.de

Specialty section:

This article was submitted to Stem Cell Research, a section of the journal Frontiers in Cell and Developmental Biology

Received: 19 March 2020 Accepted: 04 September 2020 Published: 24 September 2020

Citation:

Hauser S, Schuster S, Heuten E, Höflinger P, Admard J, Schelling Y, Velic A, Macek B, Ossowski S and Schöls L (2020) Comparative Transcriptional Profiling of Motor Neuron Disorder-Associated Genes in Various Human Cell Culture Models. Front. Cell Dev. Biol. 8:544043. doi: 10.3389/fcell.2020.544043 Disease modeling requires appropriate cellular models that best mimic the underlying pathophysiology. Human origin and an adequate expression of the disease protein are pre-requisites that support information from a model to be meaningful. In this study we investigated expression profiles of (i) PBMCs and (ii) fibroblasts as patient derived cells as well as (iii) lymphoblasts and (iv) induced pluripotent stem cells (iPSC) as immortalized sources, and (v) iPSC-derived cortical neurons to assess their aptitude to model motor neuron diseases (MNDs) including hereditary spastic paraplegia (HSP), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). We generated all five different cell types from two healthy donors and performed RNA sequencing to display expression patterns in MND-related genes. For the ten most common HSP genotypes we validated gene expression by qPCR. To verify the results on protein level, proteome analysis of fibroblasts, iPSCs and cortical neurons was performed. Depending on the specific MND gene we found largely different expression patterns. Out of 168 MND-related genes, 50 had their highest expression in iPSC-derived cortical neurons, 41 were most strongly expressed in fibroblasts, 26 in lymphoblasts, 22 in iPSCs, and 14 in PBMCs. Pathophysiologically related MNDs like HSPs associated with axonal transport deficits shared highest expression in cortical neurons. 15 MND-related genes were not detectable in any of the analyzed cell types. This may reflect the critical dependency of motor neurons on support of other cell types like oligodendrocytes which express myelin proteins like L1CAM (SPG1), PLP1 (SPG2) and MAG (SPG75) which are lacking in neurons but cause MNDs if mutated. This study provides comprehensive information on expression of genes associated with a large spectrum of MNDs. Expression profiles can be used to inform on appropriate cell models for genotype specific motor neuron research.

Keywords: motor neuron disorders, hereditary spastic paraplegia, amyotrophic lateral sclerosis, spinal muscular atrophy, gene expression, iPSCs, neurons, disease modeling

INTRODUCTION

Studies on pathophysiology of human disease and the development of new therapeutics are essentially dependent on suitable disease models. This is particularly difficult in neurological disease as often only the nervous system is affected and access to human neuronal tissue is limited to nerve and brain biopsies or post-mortem material that are notoriously rare with very limited access.

Primary patient cells like peripheral blood mononuclear cells (PBMCs) isolated from blood or fibroblasts isolated from skin biopsies are easily accessible but not primarily affected by the disease and therefore might represent pathophysiological processes only to a limited and often unknown extent. Additionally, primary patient cells possess limited growth capacity which hampers their use in largescale screening approaches. To overcome this limitation strategies of immortalizing primary patient cells have been developed early on, e.g., the transformation of PBMCs (mainly B lymphocytes) to lymphoblasts by using the Epstein-Barr virus (Miller, 1982). With the discovery of induced pluripotent stem cells (iPSCs) a novel and promising technique to generate disease-relevant and patient-specific cell types arose (Takahashi and Yamanaka, 2006). Over the last years iPSCs became a widespread tool to generate neuronal cell types that are genetically identical with patients suffering from the neurological disease of interest. iPSCs can be reprogrammed from easily accessible cell types like fibroblasts, PBMCs or keratinocytes according to well standardized procedures (Okita et al., 2013; Hauser et al., 2016a). iPSC-derived neurons have been used to model many human neurological diseases including motor neuron diseases (MNDs).

MNDs comprise three major groups of rare neurodegenerative diseases including (i) hereditary spastic paraplegia (HSP) involving primarily upper motor neurons, (ii) spinal muscular atrophy (SMA) with lower motor neuron affection, and (iii) amyotrophic lateral sclerosis (ALS) with rapid degeneration of upper and lower motor neurons. All three MNDs are genetically highly heterogeneous and split up into more than 80 genotypes of HSP, at least 30 genes causing ALS and 18 genes associated with either proximal or distal SMA (Prior et al., 1993; Kinsley and Siddique, 2015; Hedera, 2018). Further, MNDs show a substantial overlap with other disease groups like cerebellar ataxias, leukoencephalopathies and hereditary peripheral neuropathies (Synofzik and Schüle, 2017). In total more than 160 genes related to motor neuron impairment are known to date.

Until the discovery of iPSCs, research on MND mostly focused on mouse models and cell culture models using immortalized murine and human cell lines. Animal models are advantageous in providing an *in vivo* system with its whole complexity but differences between species are huge and transferability to human disease is difficult. This is especially true in the context of neurological disorders. The hope that mouse models mimic human disease pathology has been disappointing in particular for MNDs since most mouse models did not develop motor function defects or preclinical drug trials in mouse models were not successfully transferable to human studies (reviewed in Genc et al., 2019).

The potential of iPSC to generate a patient-specific cell model that represents the cell type affected by the disease of interest with the same genetic background opened new possibilities to study MND in a human neuronal cell culture model (reviewed in Denton et al., 2016). For example, analysis of SPAST-deficient neurons generated from SPG4 patients revealed pathophysiological axonal defects like axonal swellings, a hallmark of HSP disease pathology, in human iPSC-derived neurons (Havlicek et al., 2013; Denton et al., 2014). Further, in a study of SPG5, iPSC-derived neurons were employed to decipher the neurotoxic role of oxysterols that is likely to drive pathogenesis in this subtype of HSP (Schöls et al., 2017). Additionally, iPSC-derived neurons have been used for pharmacological screens to identify novel targets for the treatment of MNDs e.g., in SPG4 and SPG11 (Pozner et al., 2018; Rehbach et al., 2019). iPSCderived motor neurons and cortical neurons have also been used to mimic familial as well as sporadic forms of ALS. Observed phenotypes range from e.g., cytoskeletal defects, impaired axonal transport, cell death and vulnerability, ER stress and mitochondrial dysfunction (reviewed in Guo et al., 2017).

To choose an adequate disease model is of utmost importance for medical research. The presence of disease-related molecules is a pre-requisite of meaningful cell models. Using RNA-Sequencing (RNA-Seq) analyses we here compared the transcript expression profiles of more than 160 MND-related genes including all spastic paraplegia genes (SPGs), SMA genes and ALS genes known so far in biosamples of two independent healthy individuals including (i) PBMCs and (ii) fibroblasts as primary cells, (iii) lymphoblasts and (iv) iPSCs as immortalized cell lines as well as, and (v) iPSCderived cortical projection neurons representing a cell type predominantly affected in HSP and ALS. This dataset may help to inform about the ideal source of a patient-specific human cell culture that endogenously expresses the gene of interest to model MNDs.

MATERIALS AND METHODS

Isolation of Primary Cells

The study has been approved by the Ethics Committee of the University of Tübingen (598/2011BO1). Informed consent was obtained from all participants.

Fibroblasts were obtained from skin biopsies of two healthy individuals (Donor 1: age: 46, gender: female/Donor 2: age: 37 gender: female). Skin tissue was dissected and cultivated in a 25 cm^2 tissue culture flask containing Dulbecco's modified eagle's medium (DMEM) high glucose (Life technologies) with 10% fetal bovine serum (FBS, Life technologies) (fibroblast medium) for 10 days at 37°C and 5% CO₂. Fibroblast expansion was achieved by medium change every 2–3 days. PBMCs were isolated from whole blood of the same healthy donors as fibroblasts using a classical density gradient centrifugation with Ficoll (Ficoll Paque-PLUS, GE Healthcare) according to manufacturer's guidelines.

Transformation of PBMCs to Lymphoblasts

Immortalized lymphoblast cell lines were generated by infection of PBMCs (mainly B lymphocytes) using the EBV (Pelloquin et al., 1986). In brief, separated PBMCs were resuspended in 2 ml sterile EBV-containing supernatant of B95-8 cells and incubated for 30 min at 40°C. EBV-transformed lymphocytes (lymphoblasts) were cultivated in RPMI medium (Sigma-Aldrich) containing 20% FBS, 1% Penicillin/Streptomycin (Biochrom), 1 μ g/ml Cyclosporin A (Sigma-Aldrich), 1 mM sodium pyruvate (Sigma-Aldrich), 20 mM HEPES (Sigma-Aldrich) and 1% L-glutamine (Merck). Lymphoblasts were frozen in cryopreservation medium containing of 90% FBS supplemented with 10% DMSO (Sigma-Aldrich).

Reprogramming of Fibroblasts to iPSCs

Reprogramming was achieved by electroporation of 1×10^5 fibroblasts with 1 µg of episomal plasmids (pCXLE-hUL, pCXLE-hSK, and pCXLE-hOCT4) as described by Okita et al. (2011). 1 day after electroporation fibroblast growth factor-2 (FGF-2, 2 ng/mL, Peprotech) was supplemented to the fibroblast media. The following day cells were cultivated in Essential 8 (E8) medium supplemented with 100 µM sodium butyrate (Sigma-Aldrich) with media change every other day. Approx. 3–4 weeks after electroporation iPSC colonies were manually picked and further expanded on Matrigel-coated well plates. Splitting and replating of iPSCs was achieved by adding PBS/EDTA (0.02% EDTA in PBS). iPSCs were genomically and functionally analyzed according to (Hauser et al., 2016b).

Differentiation of iPSCs to Cortical Neurons

Induced pluripotent stem cells were differentiated to neurons of cortical layer V and VI according to published protocols with minor modifications (Shi et al., 2012; Rehbach et al., 2019). Briefly, iPSCs were seeded at a density of 3×10^5 cells per cm² in E8 medium supplemented with 10 μ M Y-27632 (Selleckchem). Neural induction was obtained by supplementation of SMAD inhibitors [10 µM SB431542 (Sigma-Aldrich) and 500 nM LDN-193189 (Sigma-Aldrich)] to 3N medium for 10 days. On day 10, cells were split in a 1:3 ratio and further expanded in 3N medium including 20 ng/ml FGF-2 for 2 days. Until day 27, cells were cultivated in 3N medium with media change every other day. On day 27, cells were dissociated using Accutase (Sigma-Aldrich) and replated at a density of $\sim 8 \times 10^5$ cells per cm². The following day, 10 µM PD0325901 (Tocris) and 10 µM DAPT (Sigma Aldrich) was added to 3N medium with an additional media change at day 30. From day 32 onward 3N medium was changed every other day and RNA of cortical neurons was isolated at day 37 of differentiation.

Immunocytochemistry

Cells were fixed with 4% paraformaldehyde (PFA, Merck Millipore) for 15 min and subsequently washed with After permeabilization and blocking with 5% PBS. BSA (Sigma Aldrich) and 0.1% Triton X-100 (Carl Roth) in PBS, cells were stained with: anti-Vimentin (rabbit, 1:100, 5741S, CST), anti-OCT4 (rabbit, 1:100, 11263-1-AP, Proteintech), anti-TRA1-81 (mouse, 1:500, MAB4381, Merck Millipore), anti-ß-III-tubulin (TUJ, mouse, 1:1000, T8660, Sigma Aldrich), anti-TBR1 (rabbit, 1:200, ab31940, Abcam) and/or anti-CTIP2 (rat, 1:200, ab18465, Abcam). After an additional washing step, Alexa-Fluor conjugated secondary antibodies (Invitrogen) were applied. Nuclei were stained with Hoechst 33258 staining (1:10.000, H1398, Invitrogen). Coverslips were mounted with Dako Mounting Solution (Agilent Dako) and images acquired using Zeiss Observer Z1 fluorescence microscope (Carl Zeiss).

RNA-Sequencing Analysis

RNA isolation of cells (PBMCs, lymphoblasts, fibroblasts, iPSCs, iPSC-derived cortical neurons) was performed by using the RNeasy Mini Kit (Qiagen) according to the manufacturer's guidelines. Further purification of isolated RNA was achieved with TruSeq mRNA v2Kit (polyA) (Illumina). RNA samples (1 sample per donor and cell type) were sequenced on a HiSeq2500 (Illumina) by DeCODE genetics (Reykjavik, Iceland).

For further expression analysis and to calculate the sample similarity a multi-dimensional scaling (MDS) plot of all RNA-Seq samples was prepared. For comparison of 168 MND-related genes, RPKMs (Reads Per Kilobase Million) for each transcript and cell type were calculated.

For GO term analysis the total number of genes with a mean expression >3 RPKMs was determined for each Gene Ontology category and cell type, resulting in a GO term coverage metric for MND-related gene sets.

For single cell RNA sequencing comparison TPM (Transcripts Per Kilobase Million) normalized gene expression values of cells and reference scRNA samples were used for pairwise comparisons to calculate Spearman's rank correlation coefficients as a measure for sample similarity. Wilcoxon's rank-sum test was applied on correlation coefficients to determine significantly higher similarity values than the background of all comparisons. Heatmaps were used to show significances as –log 10 *p*-values.

All images were generated by using GraphPad Prism.

qRT-PCR Validation

500 ng isolated RNA of each sample was reverse-transcribed to cDNA by using the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific) according to manufacturer's instructions. Real-time qPCR was performed in triplicates by adding 2 μ l primer pairs (2 μ M) and 5 μ l SYBR Green Select Master Mix (Applied Biosystems) to 3 μ l cDNA (1.25 ng/ μ l). For amplification the following primers were used:

Primer	Forward sequence	Reverse sequence
ATL-1/	CAGTCCAAGT	AATCAACTGAT
SPG3	CCTCATTGTC	TCCTGGTTGTA
BSCL2/	TTCTACTAC	CAGCTCAAG
SPG17	AGGACCGACTG	CTCTAAGGTAAC
CYP7B1/	CAGTTCTTCTT	TGCAACTGA
SPG5	GGTGGAAAGTA	CTGATGCTAAA
FA2H/	TGGGAGAGAAG	GGGACACT
SPG35	TACGATGAG	GTACCAGACA
GAPDH	TCACCAGGGC	GACAAGCTT
	TGCTTTTAAC	CCCGTTCTCAG
KIF5A/	GTCACCAAC	CCAGGTCCA
SPG10	ATGAATGAACAC	CCAGATACA
REEP1/	CCTTTGTTG	CAGACAATCA
SPG31	GTTTCCATTCTAT	TCGATTTCCTTT
SPAST/	ATAGTTACAGG	ACGTCCGTT
SPG4	ACAAGGTGAAC	TGTGACTTG
SPG7/	CAGGATTCTTT	CCATCTTCCCAT
SPG7	GGAAATGCC	CCACAAT
SPG11/	GTATTTCAG	GGCTTTCCAAGA
SPG11	GCAACACCCA	CCTATCAAT
TBP	CTTCGGAGAG	CACGAAGTGC
	TTCTGGGATTG	AATGGTCTTTAG
ZFYVE26/	ATACAGC	TCTGTAAGAG
SPG15	AGAGCAGCAAC	CTTGAGAACATC

Real-time qPCR was performed on the Viia7 Real-Time PCR System (Applied Biosystems) applying the following qRT-PCR program: 50°C for 2 min, 95°C for 2 min, 40 cycles of 95°C for 1 s, 60°C for 30 s and 72°C for 5 s, followed by 95°C for 15 s, 60°C for 1 min and 95°C for 15 s. Melting curve analysis confirmed the specificity of the PCR products. Further analysis was performed with QuantStudio Software V1.3 (Thermo Fisher Scientific) and visualized and statistically analyzed using GraphPad Prism. For statistical analysis One-way ANOVA was applied. *P*-values were corrected for multiple comparisons and P < 0.05 was considered statistically significant.

NanoLC-MS/MS Analysis and Data Processing

For mass spectrometry pellets of fibroblasts, iPSCs and CNs were lysed for 45 min at 4°C in RIPA buffer (Sigma Aldrich) including $1 \times$ cOmplete protease inhibitor cocktail (PI) (Roche). Protein concentration was determined using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) according to manufacturer's guidelines.

Protein extracts were purified using SDS PAGE (Invitrogen). Coomassie-stained gel pieces were excised and in-gel digested using trypsin as described previously (Borchert et al., 2010). After desalting using C18 Stage tips (Rappsilber et al., 2007) extracted peptides were separated on an Easy-nLC 1200 system coupled to a Q Exactive HF mass spectrometer (both Thermo Fisher Scientific) as described elsewhere (Kliza et al., 2017) with slight modifications: The peptide mixtures were separated using a 57 min segmented gradient from to 10-33-50-90% of HPLC solvent B (80% acetonitrile in 0.1% formic acid) in HPLC solvent A (0.1% formic acid) at a flow rate of 200 nl/min. The 12 most intense precursor ions were sequentially fragmented in each scan cycle using higher energy collisional dissociation (HCD) fragmentation. Each samples was measured as technical triplicate.

Acquired MS spectra were processed with MaxQuant software package version 1.6.7.0 (Cox and Mann, 2008) with integrated Andromeda search engine (Cox et al., 2011). MS/MS spectra were searched against a target-decoy Uniprot database consisting of 95972 protein entries from Homo sapiens and 286 commonly observed contaminants. Database search was performed against a target-decoy Roseburia hominis database obtained from Uniprot, containing 11,460 protein entries and 286 commonly observed contaminants. Endoprotease trypsin was defined as protease with a maximum of two missed cleavages. Oxidation of methionine and N-terminal acetylation were specified as variable modifications, whereas carbamidomethylation on cysteine was set as fixed modification. Initial maximum allowed mass tolerance was set to 4.5 parts per million (ppm) for precursor ions and 20 ppm for fragment ions. Peptide, protein and modification site identifications were reported at a false discovery rate (FDR) of 0.01, estimated by the target/decoy approach (Elias and Gygi). The iBAQ (Intensity Based Absolute Quantification) and LFQ (Label-Free Quantification) algorithms as was the 'match between runs' option were enabled (Luber et al., 2010; Schwanhausser et al., 2011).

RESULTS

To analyze MND-related gene expression in different cell types of the same individual PBMC as well as fibroblasts (F) from two healthy donors were isolated from whole blood and skin biopsies. An immortalized lymphoblast cell line (LB) was generated by infection of PBMCs using the Epstein-Barr Virus (EBV). Fibroblasts were reprogrammed to iPSCs and further differentiated to cortical projection neurons (CN) (Figure 1A). By this, we were able to compare various cell types ranging from easily accessible primary cells over immortalized cell lines to cell types affected by MNDs. The identity of fibroblasts, iPSCs and CNs was further validated by immunocytochemical stainings of typical markers (Figure 1B). Fibroblasts showed typical morphology and expressed Vimentin, iPSC were characterized by expression of OCT4 and TRA1-81 and iPSC-derived cortical neurons of layer V/VI were validated by 100% TUJ- and >85% CTIP2/TBR1-positive cells.

By comparing the global RNA-Sequencing profile of the various cell types we found a highly different and cell typespecific gene expression pattern (**Figure 1C**). As expected PBMCs and lymphoblasts closely clustered together while the other analyzed cell types showed very divergent and unique global transcript profiles as shown by principal component analysis. Of interest, there was high similarity between the same cell



kilobase million) values of cell type-specific markers of the two healthy donors (1 and 2).

types of different individuals. This is also represented by the expression of cell type-specific markers (**Figure 1D**). PBMCs and lymphoblasts exclusively expressed the marker HLA-DRA (HLA class II histocompatibility antigen, DR alpha chain) and CD74 (HLA class II histocompatibility antigen gamma chain), while fibroblast could be discriminated by expression of ELN (elastin) and LOX (lysyl oxidase). Pluripotency markers like OCT4 (octamer-binding transcription factor 4) and LIN28 (lin-28 homolog A) were exclusively detectable in iPSCs, whereas

MAP2 (microtubule-associated protein 2) and NSG2 (neuronal vesicle trafficking-associated protein 2) were highly expressed solely in iPSC-derived cortical neurons. This highlights the purity of our cell culture systems and supports the validity of this analysis.

To compare the gene expression profile in the different cell types a list of 168 MND-related genes was generated. This list covered all HSP genes (SPGs) known at the time of study including 65 HSP genes (SPG1 – SPG80; SPGs



with defined chromosomal loci but unknown genes could not be analyzed), 30 ALS-related genes, 18 SMA-related genes and 55 spasticity-related genes. To normalize for sequencing depth we divided the total reads per sample by 1,000,000 (RPM – reads per million) and further normalized for gene length by dividing the RPM values of each gene by the length of the gene in kilobases (RPKM – reads per kilobase million).

A summary of all analyzed MND-related genes in an alphabetic order can be seen in Figure 2. RPKM values

ranged from 0 to 538 depending on cell type and gene of interest. For a better visualization, genes with RPKMs >105 were separately visualized (Figure 2B). We observed high variability in gene expression between cell types of the same donor and low variability between cells of the same type from different donors.

For a clearer presentation and easier comparison of the different gene expression patterns the relative expression values for each gene and disease were determined. Therefore, the mean values of both donors per gene and cell type were calculated and the highest value of each gene was set to 100% (**Figure 3**). Afterward genes were classified per disease (HSP, ALS, and SMA) and grouped according to the highest expression per cell type from high to low RPKMs.

Out of 65 HSP-related genes, 26 had their highest expression in iPSC-derived cortical neurons ranging from 2 to 328 RPKMs. two were most strongly expressed in iPSCs (range: 21 – 294 RPKMs), 19 in fibroblasts (range: 1 – 65 RPKMs), 10 in lymphoblasts (range: 6 – 63 RPKMs), and 3 in PBMCs (range: 2 – 16 RPKMs). 5 of 65 HSP-related genes were not detectable in any of the analyzed cell types.

Concerning the 30 ALS-causing genes, 9 were expressed highest in neurons (range: 4 – 90 RPKMs) whereas, 5 showed higher expression in iPSCs (range: 5 – 538 RPKMs), 5 in fibroblasts (range: 2 – 148 RPKMs), 6 in lymphoblasts (range: 3 – 511 RPKMs) and 3 in PBMCs (range: 16 – 30 RPKMs). ANG and UBQLN2 were not detectable at all.

Out of the 18 analyzed SMA-related genes, 5 were most abundant in neurons (range: 4 – 62 RPKMs), 2 in iPSCs (range: 2 – 5 RPKMs), 3 in fibroblasts (range: 2 – 41 RPKMs), 4 in lymphoblasts (range: 9 – 38 RPKMs), 1 in PBMCs (1 RPKM). 3 genes (AR, ATP7A and UBA1) were not detected in any of these cell types.

To validate and replicate the results of the RNA-Seq analysis, the 10 most common HSP genes according to a large representative HSP cohort (Schüle et al., 2016) were selected for further qRT-PCR determination and validation (**Figure 4**). Two of these genes (KIF5A and SPG11) are also associated with ALS. In general, expression profiles were found to be largely similar in RNA-Seq data and qRT-PCR for SPG3 (ATL1), SPG4 (SPAST), SPG5 (CYP7B1), SPG7 (SPG7), SPG10 (KIF5A), SPG11 (SPG11), SPG15 (ZFYVE26), SPG17 (BSCL2), SPG31 (REEP1), and SPG35 (FA2H) (**Figures 4B–K**).

For example, REEP1 was almost exclusively expressed in iPSCderived cortical neurons (CNs) while SPAST was approximately 10 times lower expressed in PBMCs, LBs, Fs and iPSCs compared to CNs. Again, a very low variability of qRT-PCR data was observed between the same cell types of two independent donors.

To further validate the results of the RNA-Seq analysis, a comparative proteomic analysis of fibroblasts, iPSCs and CNs was performed. In total, 45 out of 168 MND-related proteins were identified via an untargeted proteomics approach (**Figure 5**). Overall, protein expression nicely matches the RNA-Seq results. For example, ATL1, REEP1, and SPAST could only be identified in iPSC-derived cortical neurons while TUBA4A was exclusively expressed in iPSCs and SIL1 was only detectable in fibroblasts.

To analyze the effect of different cell types on the expression of disease-related genes of a specific pathway the expression profiles of major downstream pathological pathways like RNA-processing abnormalities, microtubule cytoskeleton organization, ER stress response, and endosome organization were assessed. For each cell type the total numbers of genes expressed in a specific Gene Ontology category was calculated, resulting in a GO term coverage metric for selected gene sets (Figure 6A). Genes with mean expression of at least 3 RPKMs were labeled as sufficiently expressed for a specific cell type. Results were normalized to the covered gene list per GO category of cortical neurons. Overall gene expression data of iPSC-derived cortical neurons shows slightly more covered genes in GO categories related to microtubule cytoskeleton organization, mRNA processing, RNA splicing and mRNA binding. PBMCs show lowest numbers of covered genes across nearly all selected categories.

To assess the purity of our bulk RNA-Seq data of generated iPSC-derived cortical neurons, the expression profiles were compared to publicly available single cell RNA sequencing data from human adult cortical samples (Darmanis et al., 2015; **Figure 6B**). The expression profile of generated iPSC-derived cortical neurons showed significantly high similarity to single cell expression patterns of cortical adult neurons ($p < 10^{-80}$), while there was no or minor similarity to astrocytes, endothelial cells, microglia, oligodendrocytes and oligodendrocyte precursor cells (OPC) of the adult human cortex. PBMCs and lymphoblasts showed no similarity to any human cortical cell type in the same comparative analysis (**Figure 6B**).

DISCUSSION

This study presents a comparative data set of the expression of >160 MND-related genes in patient-derived primary biosamples (PBMCs and fibroblasts), immortalized cell lines (lymphoblasts, iPSCs) as well as cortical neurons reflecting the cell type affected by the disease. To model diseases with patient-derived cell types is especially of interest when analyzing (patho-)physiologically relevant processes in context of the patient's mutation status. The endogenous expression of the causative gene is a pre-requisite for these studies.

In general, the direct comparison of the expression data of two independent healthy individuals showed large similarity in expression profiles for a given cell type (e.g., fibroblasts) between individuals but a huge variability within the same individual across different cell types. **Figures 2**, **3** provide an overview on expression profiles to inform on suitable cell types that express the RNA of interest of >160 MNDrelated transcripts. Cells with highest endogenous expression are recommended for further studies to compare differences in protein expression between patients and controls and its pathophysiological relevance (**Figure 7**).

The highest expression of MND-related genes varied largely between the five cell types on analysis in this study. 8.3% of MND genes were most abundant in PBMCs, 15.5% in lymphoblasts, 24.4% in fibroblasts, 13.1% in iPSCs and 29.8% are expressed highest in CNs, while 8.9% of all MND-related

UCHL1/SPG75 0 1 25 68 100 228 KIF6A/SPG10 0 0 0 7 100 74 REEP1/SPG31 0 0 0 0 0 74 SPAST/SPG31 0 0 0 0 0 0 0 SPAST/SPG31 0	в ALS
MK1FA/SPG10 1 0 0 7 100 90 MK1FA/SPG30 0 1 0 <th0< th=""> 0 <th0< th=""> <th0< t<="" th=""><th>68 100 328 KIF5A 1 0 0 7 100 9</th></th0<></th0<></th0<>	68 100 328 KIF5A 1 0 0 7 100 9
Ritep / SPG0 0 <th0< th=""> <th< td=""><td>7 100 90 MATR3 29 30 28 56 100 8</td></th<></th0<>	7 100 90 MATR3 29 30 28 56 100 8
REEER / J SPOS / SPO	53 100 74 DCTN1 28 33 82 53 100 3
American Service 13 12 12 12 12 12 12 12 12 12 12 12 13 13 13 13 14	60 100 69 TBK1 35 11 47 31 100 1
PGAP1 / SPG7 11 3 6 11 100 41 FIG4 54 71 44 75 12 ZFR / SPG7 0 1 5 26 100 30 30 30 30 30 31 44 90 30 31 100 24 8 80 100 10 30 21 30 54 86 100 54 86 100 54 86 100 54 86 100 54 86 100 54 86 100 54 86 100 54 86 100 54 86 100 56 100 54 86 100 56 54 86 100 56 55 100 11 40 100 14 100 14 100 14 100 14 100 14 <t< td=""><td>18 100 44 VAPB 31 30 61 49 100 1</td></t<>	18 100 44 VAPB 31 30 61 49 100 1
ZFR / SPG71 47 48 87 64 100 40 MEEP2 / SPG70 0 1 5 25 100 30 ALS2 7 30 54 86 44 94 100 3 1 100 5 25 100 15 25 100 100 19 SC 100 11 100 100 100 100 100 100 100 100 100 100 100 100 100 100	11 100 41 FIG4 54 71 44 75 100 1
REEP2 / SPG72 0 1 5 26 100 30 ATP13A2 / SPG78 27 25 56 500 00 25 CPT1G / SPG73 0 8 30 100 24 CPT1G / SPG73 0 0 8 30 100 19 VDR44 / SPG12 2 7 14 21 100 19 VDR44 / SPG61 2 7 14 21 100 19 VDR44 / SPG60 34 9 35 100 16 VC 25 46 63 65 100 10 100 17 TARDPB 61 86 74 100 8 100 66 4 63 100 75 8 100 16 VC 25 46 100 12 ATM3 / SPG4 100 50 284 100 64 7 100 8 100 64 7 100 64 7 100 14 4 100 11 14 14 14 14 14	64 100 40 C9orf72 86 24 8 49 100 S
ATP13A2 / SPG78 27 25 56 55 100 24 CPTVEZ / SPG38 61 40 23 100 19 RTN2 / SPG12 27 14 21 100 19 WDR48 / SPG60 63 49 39 55 100 17 KLC2 / SPG43 54 53 78 22 100 36 74 100 66 C190rt12 / SPG43 54 53 78 22 100 16 SIGMAR1 33 100 66 44 VEAL1 / SPG3 3 1 17 9 100 16 SIGMAR1 33 100 66 46 VEALNT / SPG3 34 107 9 100 18 46 65 50 100 64 74 75 100 76 36 100 14 40 17 100 78 44 100 24 47 40 50 100 64 75 100 70 66 29 26 100 100	26 100 30 ALS2 27 30 54 86 100 S
ZFYEZ7 / SPG3 63 61 40 23 000 24 CPT1C / SPG7 0 0 8 00 19 RTN2 / SPG12 2 7 14 21 000 19 WDR4 / SPG2 2 7 14 21 000 19 WDR4 / SPG2 2 7 14 21 000 17 C190rf12 / SPG4 54 53 78 25 100 16 VCP 25 44 100 16 VCP 25 44 100 74 100 76 ATL 1 / SPG3 31 44 90 37 100 8 PKH 33 310 06 64 53 100 76 AP451 / SPG4 57 55 50 0 8 PKH 33 310 66 130 14 40 25 100 14 4 4 400 2 3 100 77 100 50 28 14 14 4 4 4 100 18	55 100 25 ERBB4 0 0 3 1 100 4
CPTIC / SPG/3 0 0 0 0 0 19 RTNZ / SPG8 23 0 00 19 9 SOD1 69 71 74 100 66 WDR48 / SPG80 63 49 39 65 000 17 SOD1 69 71 74 100 66 65 74 74 100 66 65 76 76 76 78 22 100 16 SMM1 61 85 74 100 86 64 74 100 72 33 100 66 44 100 14 41 100 14 41 100 14 41 100 14 41 100 14 41 43 31 100 66 43 MPAM1 / SPG5 31 44 90 37 100 8 28 100 14 41 41 41 41 41 41 41 41 41 41 41 41 41 41 41 41 42	23 100 24 HNRNPA1 32 59 29 100 30 53
NIR2/3 SOD1	30 100 19 FUS 86 62 88 100 62 8
HUC23 J-CGB C3 C4 C10 T/ TARDBP 64 63 65 100 6 C19u112 / SPG45 24 65 78 25 100 16 SMIPA / SPG45 23 31 100 78 24 21 23 100 15 SIGMAR1 33 31 100 66 4 4 100 14 ATXU 2 38 65 100 64 86 50 78 86 100 16 86 74 100 16 86 74 100 66 44 90 31 31 100 66 44 90 31 31 100 66 44 90 31 31 100 66 44 90 31 31 100 66 46 71 71 100 60 65 100 41 44 90 31 31 100 91 42 100 100 100 100 100 100 11 40 11 100 100 100	SOD1 59 71 74 100 63 7
C130/H2/SPG3 54 53 78 25 100 16 NIPA1/SPG3 21 23 100 16 16 33 31 100 75 8 ATL1/SPG3 3 1 17 3 100 16 33 31 100 66 4 S4GALNT1/SPG3 31 44 90 37 100 8 PRH 7 5 100 64 67 DDH02/SPG45 37 64 65 35 100 8 PRH 7 5 100 64 67 AP451/SPG45 35 61 35 100 3 0PTN 79 100 52 13 65 13 65 13 9 100 11 40 14 14 0PTN 79 100 52 13 8 55 13 65 100 11 40 11 40 11 44 100 11 44 12 13 100 17 13 8 57 59 <td>47 100 17 TARDBP 64 63 65 100 64 7</td>	47 100 17 TARDBP 64 63 65 100 64 7
NPA1 / SPG5 27 49 21 23 100 16 ATL1 / SPG5 0 0 4 1 100 15 MIG2L/SPG45 7 63 64 1 100 14 MID2 / SPG45 87 65 100 64 7 8 APAMI / SPG5 31 44 90 37 100 66 44 APAMI / SPG5 31 44 90 37 100 62 63 64 7 100 62 63 64 7 100 62 63 64 7 100 60 9 9 42 64 100 90 9 100 90 13 88 65 100 61 9 61 100 90 72 33 13 100 66 10 100 72 33 13 100 100 100 100 100 100 100 100<	25 100 16 SMN1 61 86 74 100 82 5
ATL1 / SPG3 3 1 17 9 100 15 MTGC2 / SPG49 37 63 64 61 100 12 MTGC2 / SPG49 31 40 66 35 100 75 8 AP4M1 / SPG60 31 40 66 47 100 8 PRPH 7 5 100 64 7 AP4M1 / SPG60 31 40 66 47 100 6 SGSTM1 77 100 50 25 100 71 100 97	23 100 16 VCP 25 46 100 72 33 14
IddALNT1/SPG26 0 0 4 1 100 14 NT5C2/SPG45 57 63 64 61 100 12 TECPR2/SPG48 31 44 80 37 100 8 8 66 100 44 7 38 66 100 44 7 100 8 9 53 100 14 44 9 53 100 14 44 9 53 100 14 44 9 53 100 14 44 9 53 100 14 44 9 53 100 14 44 9 53 100 14 44 9 53 100 15 44 100 3 38 66 100 14 44 10 33 100 16 11 44 10 11 44 10 10 11 44 10 10 11 44 10 11 44 10 10 11 44 10 11 44 10 10<	9 100 15 SIGMAR1 33 31 100 66 48 4
NT5C2 / SPG49 57 63 64 61 100 12 ATXN2 33 65 100 64 7 TECPR2 / SPG49 37 100 8 8 51 00 8 9 7 100 8 9 9 12 11 14 40 66 47 100 8 9 9 12 100 62 63 64 7 APAM1 / SPG50 31 40 66 47 100 3 32 100 62 63 62 63 64 7 100 97 13 8 65 52 100 66 17 00 97 13 8 66 67 100 97 13 100 77 100 97 100 11 100 11 100 11 100 11 100 11 100 11 100 11 100 11 100 10 11 100 10 11 100 10 100 11 100 100<	1 100 14 CHMP2B 49 53 100 75 80 2
TECPR2 / SPG49 31 44 90 37 100 8 PRPH 7 5 100 6 6 AP4M1 / SPG50 31 40 66 47 100 6 6 5 5 100 6 7 100 6 6 6 7 100 7 6 6 7 100 7 6 6 7 100 7 6 6 7 6 7 100 7 6 6 7 100 7 6 6 7 100 7 6 7 100 7 6 7 100 7 6 7 100 7 6 7 100 7 6 7 100 7 7 6 7 100 <td>61 100 12 ATXN2 38 65 100 64 73 6</td>	61 100 12 ATXN2 38 65 100 64 73 6
DUFUZ / SFG50 31 40 66 47 100 6 AP4M1 / SFG50 31 40 66 47 100 50 28 50 28 50 28 50 28 50 28 50 28 50 28 50 28 100 50 28 100 50 28 100 50 28 100 50 28 100 100 50 28 100 100 50 28 100 11 40 11 97 100 50 28 100 11 40 11	3/ 100 8 PRPH 7 5 100 41 4 2
Ar4st / SPG52 85 61 35 44 100 3 BSC12/SPG74 95 60 65 82 100 2 HSC12/SPG74 95 60 66 82 100 2 HSC12/SPG74 66 66 73 100 97 13 8 GBA2/SPG46 66 66 73 100 97 13 8 ALDHISA1/SPG4 66 66 73 100 97 30 Albored Albore	33 100 8 PFN1 32 100 62 63 6 51
IBA57 / SPG74 B3 60 65 82 100 2 OPTN 79 100 97 13 8 BSCL2 / SPG17 53 57 39 26 100 2 TUBAA4 97 100 97 13 8 HSPD1 / SPG13 13 52 30 100 97 21 NEH 28 100 11 40 1 GBA2 / SPG46 66 66 73 100 97 21 NEH 91 100 29 57 6 ALDH18A1 / SPG3 15 52 100 66 19 65 SETX 100 87 84 41 2 8 SPG11 100 72 41 28 30 AMG 0	47 100 6 SQSTM1 77 100 50 28 19 3
BSC12/SPC17 63 57 39 28 100 2 TUBAAA 97 100 9 42 0 HSPD1/SPC13 13 52 30 100 18 294 CHCHD10 28 100 11 40 1 BBA2/SPC46 66 66 73 100 98 42 100 21 NEFH 91 100 29 57 6 ALDH18A1/SPC40 0 78 66 19 65 SETX 100 87 44 12 28 30 44 12 28 30 44 12 28 30 ANG 0 <td>82 100 2 OPTN 79 100 97 13 80 3</td>	82 100 2 OPTN 79 100 97 13 80 3
HSPD1 / SPC13 13 52 30 100 18 294 CHCHD10 28 100 11 40 1 ALDH18A1 / SPG9 15 52 100 66 19 65 SETX 100 70 66 29 2 UBAP / SPC67 26 60 00 42 41 38 SETX 100 70 66 29 2 TFG / SPC67 26 60 100 42 41 38 SPC11 100 72 41 28 3 AMP02 / SPG63 30 44 100 27 56 22 100 72 41 28 3 USP8 / SPG69 86 84 100 82 45 12 2 2 2 5 0 <td< td=""><td>26 100 2 TUBA4A 97 100 9 42 0 2</td></td<>	26 100 2 TUBA4A 97 100 9 42 0 2
GBA2 / SPC46 66 66 73 100 97 21 Part of the second seco	100 18 294 CHCHD10 28 100 11 40 11 1
ALDH18A1 / SPG9 15 52 100 66 19 65 UBAP / SPG80 60 78 100 98 75 39 TFG / SPG57 26 60 100 42 41 38 AMPD2 / SPG63 30 44 100 27 56 22 MAPD2 / SPG63 30 44 100 27 56 22 KIAA0196 / SPG8 60 53 100 51 11 19 SPG20 / SPG20 68 17 100 87 31 13 USP8 / SPG63 39 56 100 49 74 9 9 ARSI / SPG64 10 28 0 7 10 100 28 0 7 MARS / SPG63 3 15 100 5 12 5 101 144 0 10 104 144 0 10 104 144 0 10 104 144 0 104 144 0 104 144 114 104 <t< td=""><td>100 97 21 NEFH 91 100 29 57 67 3</td></t<>	100 97 21 NEFH 91 100 29 57 67 3
UBAP / SPG80 60 78 100 98 75 39 TFG / SPG57 26 60 100 42 41 38 38 38 39 39 39 30 34 41 22 31 38 30 44 100 27 56 22 30 100 61 39 19 9 30 30 44 100 27 56 22 30 100 51 11 19 30 AMPD2 / SPG80 66 53 100 61 39 19 19 9 30 40 0	66 19 65 SETX 100 70 66 29 29 3
IFG (SPG8) 26 60 100 42 41 38 KIF1C (SPG8) 30 100 79 9 30 <	98 75 39 TRPM7 100 87 84 41 25 1
AMPC / SPG8 24 10 10 19 3 3 ANG 0	42 41 38 SPG11 100 72 41 28 36 1
KIAA0196 / SPG8 S0 S7 100 21 33 12 ERLIM1 / SPG62 22 30 100 51 11 19 SPG20 / SPG20 68 17 100 87 31 13 USR8 / SPG58 86 84 100 82 45 12 SLC33A1 / SPG42 42 48 100 29 27 11 ERLIN2 / SPG58 39 56 100 49 74 9 DSTYK / SPG23 47 10 100 33 93 9 ARSI / SPG66 0 0 100 28 0 7 CYP2B1 / SPG5 3 15 100 5 12 5 C12orf6 / SPG55 91 81 100 62 56 3 GJC2 / SPG44 12 11 100 10 90 1 MARS / SPG70 38 100 64 77 28 63 SMN1 61 86 76 11 MARS / SPG70 38	79 9 30 ANG 0 0 0 0 0
ERLIMI / SPG62 22 30 100 81 11 13 SPG20 / SPG20 68 17 100 87 31 13 USP8 / SPG59 68 84 100 82 45 12 SLC33A1 / SPG42 42 48 100 29 27 11 ERLIM2 / SPG18 37 51 100 81 33 11 VPS37A / SPG53 39 56 100 49 74 9 ARSI / SPG66 0 0 100 28 0 7 ARSI / SPG66 0 0 100 28 0 7 C/P7DI / SPG66 0 0 11 40 61 31 95 50 11 C/P7DI / SPG66 10 10 90 1 10 10 10 10 10 10 10 11 10 11 10 10 14 10 11 10 10 10 11	61 39 19 UBQLN2 0 0 0 0 0
SPG20 / SPG20 68 17 100 87 31 13 USP8 / SPG69 86 84 100 82 45 12 SLC33A1 / SPG42 42 48 100 29 27 11 ERLIN2 / SPG18 37 51 100 81 33 11 VPS37A / SPG63 39 56 100 49 74 9 7 ARSI / SPG60 0 100 28 0 7 7 7 AP4E1 / SPG51 76 75 100 41 40 6 5 C12orf65 / SPG56 91 81 100 48 76 5 7 9 GJ22 / SPG44 12 11 100 10 90 1 16HmBP2 82 85 90 76 11 MARS / SPG76 38 100 64 77 28 63 SMN1 61 86 74 100 8 CAPN1 / SPG76 42 100 86 79 52 26 SMM2	
USP8 / SPG59 86 84 100 82 45 12 SLC33A1 / SPG42 42 48 100 29 27 11 USP8 / SPG53 37 51 100 81 33 11 VPS37A / SPG53 39 56 100 49 74 9 7 DSTYK / SPG23 47 10 100 33 93 9 ARSI / SPG66 0 0 100 28 0 7 AP4E1 / SPG51 76 75 100 41 40 66 DNAJB2 72 92 56 30 10 C12orf65 / SPG55 91 81 100 48 76 5 0 1 IGHMBP2 82 85 90 76 10 G JC2 / SPG44 12 11 100 62 56 3 161 86 74 100 82 85 90 76 161 86 74 100 82 85 90 76 16	87 31 13 AM V 10 50 CV AK
SLC33A1 / SPG42 42 48 100 29 27 11 ERLIN2 / SPG18 37 51 100 81 33 11 VPS37A / SPG53 39 56 100 49 74 9 ARSI / SPG66 0 0 100 28 0 7 AP4E1 / SPG51 76 75 100 51 12 5 CYP7B1 / SPG5 3 15 100 5 12 5 CYP7B1 / SPG5 3 15 100 5 12 5 CYP2U1 / SPG56 68 46 100 62 56 3 GJC2 / SPG44 12 11 100 10 90 1 MARS / SPG70 38 100 64 77 28 63 SIGMA1 81 84 100 86 CAPN1 / SPG76 42 100 86 79 52 26 SIGMA1 33 31 100 66 44 100 53 8 AP521 / SPG48 77	82 45 12 X X
ERLIN2 / SPG18 37 51 100 81 33 11 VPS37A / SPG53 39 56 100 49 74 9 9 DSTYK / SPG23 47 10 100 33 93 9 9 ARSI / SPG66 0 0 100 28 0 7 9 AP4E1 / SPG51 76 75 100 41 40 6 0 0 10 28 0 7 C12orf65 / SPG55 91 81 100 62 56 3 16 0 14 40 6 248 51 84 10 GJC2 / SPG44 12 11 100 10 90 1 16HMBP2 82 85 90 76 11 MARS / SPG70 38 100 64 77 28 63 SIMN1 61 86 74 100 88 SIMN2 82 95 92 100 8 ENTPD1 / SPG64 14 100 65 22 55	29 27 11
VPS3/A / SPG53 39 56 100 49 74 9 DSTYK / SPG23 47 10 100 33 93 9 9 ARSI / SPG66 0 0 100 28 0 7 AP4E1 / SPG51 76 75 100 41 40 6 CYP7B1 / SPG5 3 15 100 5 12 5 VAPB 62 48 51 84 10 C12orf65 / SPG55 91 81 100 48 76 25 63 SMN1 61 86 74 100 8 CAPN1 / SPG76 42 100 66 70 52 26 SMN2 82 95 92 100 88 CAPN1 / SPG76 42 100 66 70 52 26 SMN2 82 95 92 100 88 CAPN1 / SPG76 41 100 6 10 19 24 SIGMAR1 33 31 100 66 44 40 100 55 92	
ARSI / SPG23 47 100 100 33 93 9 ARSI / SPG66 0 0 100 28 0 7 AP4E1 / SPG51 76 75 100 41 40 6 CYP7B1 / SPG5 3 15 100 5 12 5 C12orf65 / SPG55 91 81 100 48 76 5 CYP2U1 / SPG56 68 46 100 62 56 3 GJC2 / SPG44 12 11 100 10 90 1 IGHMBP2 82 85 90 76 10 MARS / SPG70 38 100 64 77 28 63 SMN1 61 86 74 100 8 CAPN1 / SPG76 42 100 86 79 52 26 SIGMAR1 33 31 100 66 44 AP521 / SPG48 77 100 69 23 25 15 TRPV4 4 0 100 50 76 AP521 / S	49 74 9 C SMA
ARKS1 / SPG50 0 0 0 0 100 23 0	
CYP7B1 / SPG5 3 15 100 5 12 5 DNAJB2 72 92 56 30 11 C12orf65 / SPG55 91 81 100 48 76 5 VAPB 62 48 51 84 100 CYP2U1 / SPG56 68 46 100 62 56 3 VAPB 62 48 51 84 100 GJC2 / SPG44 12 11 100 10 90 1 IGHMBP2 82 85 90 76 11 MARS / SPG70 38 100 64 77 28 63 SMN1 61 86 74 100 8 ENTPD1 / SPG64 14 100 6 10 19 24 SIGMAR1 33 31 100 66 44 ACP33 / SPG21 55 100 75 56 47 22 BICD2 63 44 100 53 8 PNPLA6 / SPG39 99 100 82 76 78 12 <td< td=""><td>28 0 7 DYNC1H1 40 31 95 50 100 6</td></td<>	28 0 7 DYNC1H1 40 31 95 50 100 6
C12orf65 / SPG55 91 81 100 48 76 5 CYP2U1 / SPG56 68 46 100 62 56 3 IGHMBP2 82 85 90 76 14 MARS / SPG70 38 100 64 77 28 63 SMN1 61 86 74 100 8 76 14 MARS / SPG70 38 100 64 77 28 63 SMN1 61 86 74 100 8 CAPN1 / SPG76 42 100 86 79 52 26 SMN1 81 100 66 4 ACP33 / SPG21 55 100 75 56 47 22 BICD2 63 44 100 53 8 PNPLA6 / SPG39 99 100 82 77 33 13 ASAH1 46 100 46 24 4 DDHD1 / SPG28 52 100 37 17 38 9 TRIP4 81 100 56 58 6	5 12 5 DNAJB2 72 92 56 30 100 2
CYP2U1 / SPG56 68 46 100 62 56 3 PLEKHG5 18 4 27 87 10 GJC2 / SPG44 12 11 100 10 90 1 IGHMBP2 82 85 90 76 10 MARS / SPG70 38 100 64 77 28 63 SMN1 61 86 74 100 82 CAPN1 / SPG76 42 100 86 79 52 26 SMN1 81 44 27 87 10 ACP33 / SPG21 55 100 75 56 47 22 BICD2 63 44 100 53 88 AP5Z1 / SPG48 77 100 69 23 25 15 TRPV4 4 0 100 50 5 RAB3GAP2 / SPG49 61 100 82 76 78 12 CHCHD10 28 100 11 40 1 10 5 5 6 ASAH1 46 100 5 58	48 76 5 VAPB 62 48 51 84 100 1
GJC2 / SPG44 12 11 100 10 90 1 10 10 90 1 MARS / SPG70 38 100 64 77 28 63 SMN1 61 86 74 100 8 CAPN1 / SPG76 42 100 86 79 52 26 SMN1 61 86 74 100 8 ENTPD1 / SPG64 14 100 6 10 19 24 SIGMAR1 33 31 100 66 4 ACP33 / SPG21 55 100 75 56 47 22 BICD2 63 44 100 53 8 PNPLA6 / SPG39 99 100 82 77 33 13 ASAH1 46 100 46 24 4 DDHD1 / SPG28 52 100 37 17 38 9 TRIP4 81 100 96 59 9 FARS2 / SPG77 65 100 78 74 73 6 ASCC1 39 100 <td>62 56 3 PLEKHG5 18 4 27 87 100 7</td>	62 56 3 PLEKHG5 18 4 27 87 100 7
MARS / SPG70 38 100 64 77 28 63 SMN1 61 86 74 100 8 CAPN1 / SPG76 42 100 86 79 52 26 SMN2 82 95 92 100 8 ENTPD1 / SPG64 14 100 6 10 19 24 SIGMAR1 33 31 100 66 44 ACP33 / SPG21 55 100 75 56 47 22 BICD2 63 44 100 53 8 PNPLA6 / SPG39 99 100 82 76 78 12 BICD2 63 44 100 50 7 RAB3GAP2 / SPG39 99 100 82 76 78 12 CHCHD10 28 100 11 40 1 ZFYVE26 / SPG15 96 100 48 62 59 6 ASCC1 39 100 56 58 6 SPG11 / SPG11 100 72 41 28 36 16	10 90 1 IGHMBP2 82 85 90 76 100 4
CAPN1 / SPG/6 42 100 86 79 52 26 SMN2 82 95 92 100 8 ENTPD1 / SPG64 14 100 6 10 19 24 SIGMAR1 33 31 100 66 4 ACP33 / SPG21 55 100 75 56 47 22 BICD2 63 44 100 53 8 PNPLA6 / SPG39 99 100 82 77 33 13 ASAH1 46 100 40 50 50 74 73 73 13 ASAH1 46 100 42 4 DDHD1 / SPG28 52 100 37 17 38 9 77 73 66 ASC1 39 100 56 58 6 FARS2 / SPG15 96 100 48 62 59 6 ASC1 39 100 56 58 6 SPG11 / SPG11 100 72 41 28 36 16 NAIP 100 16	77 28 63 SMN1 61 86 74 100 82
ENTPD // SPG04 14 100 6 10 19 24 SIGMAR1 33 31 100 66 4 ACP33 / SPG21 55 100 75 56 47 22 63 44 100 53 8 AP521 / SPG48 77 100 69 23 25 15 TRPV4 4 0 100 50 56 PNPLA6 / SPG39 99 100 82 76 78 12 TRPV4 4 0 100 50 50 PA52 / SPG39 61 100 82 76 78 12 CHCHD10 28 100 11 40 1 ZFYVE26 / SPG15 96 100 48 62 59 6 ASCC1 39 100 56 58 6 SPG11 / SPG11 100 72 41 28 36 16 NAIP 100 16 11 8 3 SPG11 / SPG37 100 63 91 77 65 11 AR 0 </td <td>79 52 26 SMN2 82 95 92 100 87 2</td>	79 52 26 SMN2 82 95 92 100 87 2
AP521 / SPG48 77 100 69 23 25 15 TRPV4 4 0 100 50 44 PNPLA6 / SPG39 99 100 82 77 33 13 13 TRPV4 4 0 100 50 44 PNPLA6 / SPG39 99 100 82 77 33 13 ASAH1 46 100 50 44 4 46 100 50 44 4 46 100 50 44 46 46 24 4 46 46 24 4 46 46 24 4 46 46 24 4 46 46 24 4 46 46 24 4 46 46 24 4 46 46 24 4 46 46 46 46 40 46 46 46 46 46 46 46 46 46 44 46 46 46 46 46 46 46 46 46 46 46 46	56 47 22 SIGMAR1 33 31 100 66 48 4
Child Child / SPG39 10 10 10 10 10 10 10 50 20 10 10 10 50 20 10 50 20 10 50 20 10 50 20 100 50 20 100 50 20 100 50 20 100 50 20 20 100 50 20 20 100 50 20 20 100 50 20 20 100 50 20	30 47 22 BICD2 63 44 100 53 86 1 23 25 15 50 15 50 15 50 15 50 15 50 16 16 16 100 53 86 1 16 1
RAB3GAP2 / SPG69 61 100 82 76 78 12 ASAH1 46 100 46 24 4 DDHD1 / SPG28 52 100 37 17 38 9 12 ASAH1 46 100 46 24 4 DDHD1 / SPG28 52 100 37 17 38 9 12 CHCHD10 28 100 11 40 1 ZFYVE26 / SPG15 96 100 48 62 59 6 ASCC1 39 100 56 58 6 SPG11 / SPG11 100 72 41 28 36 16 NAIP 100 16 11 8 3 SPG7 / SPG7 100 63 91 77 65 11 AR 0	
DDHD1 / SPG28 52 100 37 17 38 9 CHCHD10 28 100 11 40 1 ZFYVE26 / SPG15 96 100 48 62 59 6 TRIP4 81 100 96 59 9 FARS2 / SPG77 65 100 78 74 73 6 ASCC1 39 100 56 58 6 SPG11 / SPG11 100 72 41 28 36 16 NAIP 100 16 11 8 3 SPG7 / SPG7 100 63 91 77 65 11 AR 0	76 78 12 ASAH1 46 100 46 24 44 3
ZFYVE26 / SPG15 96 100 48 62 59 6 TRIP4 81 100 96 59 9 FARS2 / SPG77 65 100 78 74 73 6 ASCC1 39 100 56 58 6 SPG11 / SPG11 100 72 41 28 36 16 NAIP 100 16 11 8 3 SPG7 / SPG7 100 63 91 77 65 11 AR 0 <td>17 38 9 CHCHD10 28 100 11 40 11 1</td>	17 38 9 CHCHD10 28 100 11 40 11 1
FARS2 / SPG77 65 100 78 74 73 6 ASCC1 39 100 56 58 6 SPG11 / SPG11 100 72 41 28 36 16 NAIP 100 16 11 8 3 SPG7 / SPG7 100 63 91 77 65 11 AR 0<	62 59 6 IRIP4 81 100 96 59 92 1
SPG11 / SPG11 100 72 41 28 36 16 NAIP 100 16 11 8 3 SPG7 / SPG7 100 63 91 77 65 11 AR 0 <	74 73 6 ASCC1 39 100 56 58 68 9
SPG//SPG/ 100 63 91 77 65 11 AR 0 0 0 0 0 AP4B1/SPG37 100 33 21 5 19 2 ATP7A 0	28 36 16 NAIP 100 16 11 8 37
AF4B1 / SPG4/ 100 33 21 5 19 2 ATP7A 0 0 0 0 FA2H / SPG35 0	11 AR 0
L1CAM / SPG1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
MAG / SPG75 0 0 0 0 0 0 0 PLP1 / SPG2 0 0 0 0 0 0 0 SLC16A2 / SPG22 0 0 0 0 0 0 0 0	
PLP1 / SPG2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	
SLC16A2 / SPG22 0 0 0 0 0 0 0	
	MC 18 4 050 CN M
	PENC 18 4 PSC CN PRKN

FIGURE 3 | Expression of (A) HSP-, (B) ALS-, and (C) SMA-related transcripts classified according to the cell type showing the highest expression. Mean value of two donors were calculated for each gene, cell type and disease and the highest value of each gene was set to 100%. For each cell type relative values (in%) are given for the respective gene. Grouping per cell type is shown from high to low RPKMs. HSP transcripts are encoded as: gene name/SPG type. Other MND-related transcripts are encoded as: gene name. PBMC, peripheral blood mononuclear cells; LB, lymphoblasts; F, fibroblasts; iPSC, induced pluripotent stem cells; CN, iPSC-derived cortical neurons; RPKMs, reads per kilobase million.



cortical neurons.

genes could not be identified in any of the analyzed cell types. Comparable distributions could also be seen for all three groups of MND with CNs being the most commonly represented cell type (HSP: 40%, ALS: 30%, SMA: 28%). An overview of all HSP, SMA and ALS genes and the respective cell type with the highest expression is provided in **Figure 7**. This clearly shows that a general statement of an ideal cell type for disease modeling of MNDs is not valid.

Nevertheless, iPSC-derived cortical neurons and/or fibroblasts are in most cases more suitable cell types compared to PBMCs or lymphoblasts.

We selected projection neurons of cortical layer V/VI for this study as they can be differentiated with high purity from iPSC and motor neurons constitute a specific subtype of projection neurons originating from cortical layer V/VI. Our differentiation protocol allowed for a reproducible generation of a largely





homogeneous neuronal cell population with 100% of cells expressing ß-III-tubulin as neuronal marker and >85% of cells being positive for CTIP2 and/or TBR1 expression indicating cortical projection neurons of layer V/VI (Rehbach et al., 2019). This allows to perform bulk RNA-Seq analysis of neurons without cross-contamination of cells of glial origin as demonstrated by the non-detection of glial markers like GFAP as well as the comparative analysis to single cell RNA-Seq data of human cortical samples. Established motor neuron protocols do not reach such an extent of purity and represent lower (rather than upper) motor neurons that are not affected in HSP (reviewed in Sances et al., 2016).

The intuitive notion that the expression of MND genes is highest in cortical neurons as the primary affected cell type in HSP and ALS is only true in \sim 30% of all MND genes. This may reflect that the function of a motor neuron and especially its extremely long axons require additional functionality of supporting cells including oligodendrocytes, microglia, astrocytes as well as peripheral Schwann cells and is further influenced by more general systemic metabolic pathways and changes. In extreme cases, especially when gene products play a role in general metabolic pathways like ARSI (SPG66) or CYP27A1 (CTX), the expression of the RNA is absent in iPSC-derived cortical neurons but is highest in fibroblasts or PBMCs (Figures 2, 3). In contrast, more easily available patient-derived cell types like fibroblasts and PBMCs do not express several relevant MND genes like SPG10 (KIF5A), SPG26 (B4GALNT1), SPG31 (REEP1), ERBB4 and PLEKHG5 and therefore disqualify as cellular models for pathogenic studies in these MNDs.

Studying the expression profiles by looking at specific clusters that share a similar cellular function as summarized by Blackstone (2018), some pathophysiologically related HSPs show similar expression profiles. HSPs associated with axonal transport deficits like SPG4 (SPAST), SPG10 (KIF5A), SPG30 (KIF1A), SPG31 (REEP1), and SPG72 (REEP2) share highest expression in cortical neurons as their primary site of action and are only low expressed or absent in all other analyzed cell types. These findings could further be validated by the proteomic analysis, where e.g., ATL1, SPAST, and REEP1 could exclusively be detected in CNs. Interestingly, some RNAs including PLP1 (SPG2), MAG (SPG75), and GFAP (Alexander disease) are expressed in none of the cell types studied here. These genes define subtypes of MNDs with primary myelin or glial dysfunction. For example PLP1 (proteolipid protein) is the primary constituent of myelin in the central nervous system (Diehl et al., 1986). In this specific subset of MND-related genes a suitable cell culture model probably requires different approaches and cell types like iPSC-derived oligodendrocytes, Schwann cells and/or astrocytes or even a co-culture or a 3-dimensional in vitro culture system to obtain meaningful and disease-relevant results (Shaltouki et al., 2013; reviewed in Douvaras et al., 2014; Kim et al., 2017; reviewed in: McComish and Caldwell, 2018).

In summary we provide a valuable dataset of more than 160 MND-related transcripts of different patient-derived biosamples, which can be employed to preselect



FIGURE 6 Pathway analysis and dataset comparison of RNA-Seq results. **(A)** Gene ontology (GO) term analysis for each cell type of major disease-related pathways. The total number of genes with a mean expression >3 RPKMs was determined and normalized to the total number of genes per GO term in cortical neurons. Numbers (e.g., 50/65) indicate the number of genes identified in cortical neurons (50) out of the total number of genes per GO term (65). **(B)** Heatmap by Wilcoxon's rank sum comparison of RNA-Seq dataset to a single cell RNA-Seq dataset of human cortical samples (Darmanis et al., 2015). Values are shown as –LOG10 *p*-values of significant differences. Bulk RNA-Seq of iPSC-derived cortical neurons display a high similarity to human adult neurons of the cortex. PBMC, peripheral blood mononuclear cells; LB, lymphoblasts; F, fibroblasts; iPSC, induced pluripotent stem cells; CN, iPSC-derived cortical neurons.



(C) SMA genes are ordered alphabetically. Color defines the cell type with the highest expression for each gene. nd, not detectable; PBMC, peripheral blood mononuclear cells; LB, lymphoblasts; F, fibroblasts; iPSC, induced pluripotent stem cells; CN, iPSC-derived cortical neurons; unknown gene – only loci identified.

a proper cellular model to potentially decipher molecular mechanism wit pathophysiological relevance and to screen for novel therapeutic targets in various types of MNDs.

DATA AVAILABILITY STATEMENT

Data can be found in NCBI using the accession number GSE157185.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of the University of Tübingen (598/2011BO1). The patients/participants provided their written informed consent to participate in this study.

REFERENCES

- Blackstone, C. (2018). Converging cellular themes for the hereditary spastic paraplegias. Curr. Opin. Neurobiol. 51, 139–146. doi: 10.1016/j.conb.2018.04. 025
- Borchert, N., Dieterich, C., Krug, K., Schutz, W., Jung, S., Nordheim, A., et al. (2010). Proteogenomics of *Pristionchus pacificus* reveals distinct proteome structure of nematode models. *Genome Res.* 20, 837–846. doi: 10.1101/gr. 103119.109
- Cox, J., and Mann, M. (2008). MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* 26, 1367–1372. doi: 10.1038/nbt.1511
- Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A., Olsen, J. V., and Mann, M. (2011). Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794–1805. doi: 10.1021/pr101065j
- Darmanis, S., Sloan, S. A., Zhang, Y., Enge, M., Caneda, C., Shuer, L. M., et al. (2015). A survey of human brain transcriptome diversity at the single cell level. *Proc. Natl. Acad. Sci. U.S.A.* 112, 7285–7290. doi: 10.1073/pnas.1507125112
- Denton, K. R., Lei, L., Grenier, J., Rodionov, V., Blackstone, C., and Li, X. J. (2014). Loss of spastin function results in disease–specific axonal defects in human pluripotent stem cell–based models of hereditary spastic paraplegia. *Stem Cells* 32, 414–423. doi: 10.1002/stem.1569
- Denton, K. R., Xu, C., Shah, H., and Li, X.-J. (2016). Modeling axonal defects in hereditary spastic paraplegia with human pluripotent stem cells. *Front. Biol.* 11:339–354. doi: 10.1007/s11515-016-1416-0
- Diehl, H.-J., Schaich, M., Budzinski, R.-M., and Stoffel, W. (1986). Individual exons encode the integral membrane domains of human myelin proteolipid protein. *Proc. Natl. Acad. Sci. U.S.A.* 83, 9807–9811. doi: 10.1073/pnas.83.24.9807
- Douvaras, P., Wang, J., Zimmer, M., Hanchuk, S., O'Bara, M. A., Sadiq, S., et al. (2014). Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis patients by induced pluripotent stem cells. *Stem Cell Reports* 3, 250–259. doi: 10.1016/j.stemcr.2014.06.012
- Genc, B., Gozutok, O., and Ozdinler, P. H. (2019). Complexity of generating mouse models to study the upper motor neurons: let us shift focus from mice to neurons. *Int. J. Mol. Sci.* 20:3848. doi: 10.3390/ijms20163848
- Guo, W., Fumagalli, L., Prior, R., and Van Den Bosch, L. (2017). Current advances and limitations in modeling ALS/FTD in a dish using induced pluripotent stem cells. *Front. Neurosci.* 11:671. doi: 10.3389/fnins.2017.00671 eCollection 2017
- Hauser, S., Erzler, M., Theurer, Y., Schuster, S., Schüle, R., and Schöls, L. (2016a). Establishment of SPAST mutant induced pluripotent stem cells (iPSCs) from a hereditary spastic paraplegia (HSP) patient. *Stem Cell Res.* 17, 485–488. doi: 10.1016/j.scr.2016.09.022

AUTHOR CONTRIBUTIONS

SH and LS: conceptualization. SH, SS, and JA: methodology. JA, AV, BM, and SO: software. SH, SS, JA, and AV: formal analysis. SH, SS, EH, PH, JA, YS, and AV: investigation. SO and BM: resources. SH: writing – original draft and visualization. SS, EH, PH, JA, AV, BM, SO, and LS: writing – review and editing. SH, SO, and LS: supervision. SH and LS: project administration. LS funding acquisition. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by an EC funded Neuromics project (F5-2012-305121) to LS and the German Ministry of Education and Research (01GM1905A) to LS and SH. LS is member of the European Reference Network for Rare Neurological Diseases-Project ID No. 739510.

- Hauser, S., Hoflinger, P., Theurer, Y., Rattay, T. W., and Schols, L. (2016b). Generation of induced pluripotent stem cells (iPSCs) from a hereditary spastic paraplegia patient carrying a homozygous Y275X mutation in CYP7B1 (SPG5). *Stem Cell Res.* 17, 437–440. doi: 10.1016/j.scr.2016.09.011
- Havlicek, S., Kohl, Z., Mishra, H. K., Prots, I., Eberhardt, E., Denguir, N., et al. (2013). Gene dosage-dependent rescue of HSP neurite defects in SPG4 patients' neurons. *Hum. Mol. Genet.* 23, 2527–2541. doi: 10.1093/hmg/ddt644
- Hedera, P. (2018). "Hereditary spastic paraplegia overview," in *GeneReviews*[®] [*Internet*], eds M. P. Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. H. Bean, K. Stephens, et al. (Seattle, WA: University of Washington).
- Kim, H.-S., Lee, J., Lee, D. Y., Kim, Y.-D., Kim, J. Y., Lim, H. J., et al. (2017). Schwann cell precursors from human pluripotent stem cells as a potential therapeutic target for myelin repair. *Stem Cell Reports* 8, 1714–1726. doi: 10.1016/j.stemcr.2017.04.011
- Kinsley, L., and Siddique, T. (2015). "Amyotrophic lateral sclerosis overview," in *GeneReviews*[®] [*Internet*], eds M. P. Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. H. Bean, K. Stephens, et al. (Seattle, WA: University of Washington).
- Kliza, K., Taumer, C., Pinzuti, I., Franz-Wachtel, M., Kunzelmann, S., Stieglitz, B., et al. (2017). Internally tagged ubiquitin: a tool to identify linear polyubiquitinmodified proteins by mass spectrometry. *Nat. Methods* 14, 504–512. doi: 10. 1038/nmeth.4228
- Luber, C. A., Cox, J., Lauterbach, H., Fancke, B., Selbach, M., Tschopp, J., et al. (2010). Quantitative proteomics reveals subset-specific viral recognition in dendritic cells. *Immunity* 32, 279–289. doi: 10.1016/j.immuni.2010. 01.013
- McComish, S. F., and Caldwell, M. A. (2018). Generation of defined neural populations from pluripotent stem cells. *Philos. Trans. R. Soc. B Biol. Sci.* 373:20170214. doi: 10.1098/rstb.2017.0214
- Miller, G. (1982). Immortalization of human lymphocytes by epstein-barr virus. *Yale J. Biol. Med.* 55, 305-310.
- Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., et al. (2011). A more efficient method to generate integrationfree human iPS cells. *Nat. Methods* 8, 409–412. doi: 10.1038/nmeth. 1591
- Okita, K., Yamakawa, T., Matsumura, Y., Sato, Y., Amano, N., Watanabe, A., et al. (2013). An efficient nonviral method to generate integration–free human–induced pluripotent stem cells from cord blood and peripheral blood cells. *Stem Cells* 31, 458–466. doi: 10.1002/stem.1293
- Pelloquin, F., Lamelin, J., and Lenoir, G. (1986). Human B lymphocytes immortalization by epstein-barr virus in the presence of cyclosporin A. *In Vitro Cell. Dev. Biol.* 22, 689–694.

- Pozner, T., Schray, A., Regensburger, M., Lie, D. C., Schlötzer-Schrehard, U., Winkler, J., et al. (2018). Tideglusib rescues neurite pathology of SPG11 iPSC derived cortical neurons. *Front. Neurosci.* 12:914. doi: 10.3389/fnins.2018. 00914
- Prior, T. W., Leach, M. E., and Finanger, E. (1993). "Spinal muscular atrophy," in *GeneReviews((R))*, eds M. P. Adam, H. H. Ardinger, R. A. Pagon, S. E. Wallace, L. J. H. Bean, K. Stephens, et al. (Seattle, WA: University of Washington).
- Rappsilber, J., Mann, M., and Ishihama, Y. (2007). Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2, 1896–1906. doi: 10.1038/nprot.2007.261
- Rehbach, K., Kesavan, J., Hauser, S., Ritzenhofen, S., Jungverdorben, J., Schüle, R., et al. (2019). Multiparametric rapid screening of neuronal process pathology for drug target identification in HSP patient-specific neurons. *Sci. Rep.* 9:9615.
- Sances, S., Bruijn, L. I., Chandran, S., Eggan, K., Ho, R., Klim, J. R., et al. (2016). Modeling ALS with motor neurons derived from human induced pluripotent stem cells. *Nat. Neurosci.* 19, 542–553. doi: 10.1038/nn.4273
- Schöls, L., Rattay, T. W., Martus, P., Meisner, C., Baets, J., Fischer, I., et al. (2017). Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial. *Brain* 140, 3112–3127.
- Schüle, R., Wiethoff, S., Martus, P., Karle, K. N., Otto, S., Klebe, S., et al. (2016). Hereditary spastic paraplegia: clinicogenetic lessons from 608 patients. *Ann. Neurol.* 79, 646–658. doi: 10.1002/ana.24611
- Schwanhausser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., et al. (2011). Global quantification of mammalian gene expression control. *Nature* 473, 337–342. doi: 10.1038/nature10098

- Shaltouki, A., Peng, J., Liu, Q., Rao, M. S., and Zeng, X. (2013). Efficient generation of astrocytes from human pluripotent stem cells in defined conditions. *Stem Cells* 31, 941–952. doi: 10.1002/stem.1334
- Shi, Y., Kirwan, P., and Livesey, F. J. (2012). Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. *Nat. Protoc.* 7, 1836-1846.
- Synofzik, M., and Schüle, R. (2017). Overcoming the divide between ataxias and spastic paraplegias: shared phenotypes, genes, and pathways. *Mov. Disord.* 32, 332–345. doi: 10.1002/mds.26944
- Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126, 663–676. doi: 10.1016/j.cell.2006.07.024

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Hauser, Schuster, Heuten, Höflinger, Admard, Schelling, Velic, Macek, Ossowski and Schöls. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.